Epidermolysis Bullosa Acquisita following Bullous Pemphigoid, Successfully Treated with the Anti-CD20 Monoclonal Antibody Rituximab

Wallet-Faber, N.; Franck, N.; Batteux, Frédéric; Mateus, Christine; Gilbert, Danièle; Carlotti, A.; Avril, M. F.; Dupin, Nicolas

doi:10.1159/000106585

Cited by 30 publications

(6 citation statements)

References 36 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rituximab has also been used in the treatment for severe or treatment‐refractory forms of epidermolysis bullosa acquisita, but data are limited (Niedermeier et al , 2006; Schmidt et al , 2006; Crichlow et al , 2007; Sadler et al , 2007; Wallet‐Faber et al , 2007; Cavailhes et al , 2009; Saha et al , 2009; Le Roux‐Villet et al , 2011; Li et al , 2011). Complete and partial responses have been observed, but more data are required to define its use in this condition.…”

Section: Vesiculobullous Diseasesmentioning

confidence: 99%

Biologics in oral medicine: ulcerative disorders

O’Neill¹,

Scully²

2012

Oral Diseases

View full text Add to dashboard Cite

Inflammatory ulcerative diseases of the oral mucosa are wide ranging but include especially aphthous and aphthous-like ulceration, vesiculobullous disorders and erosive lichen planus (LP). While most patients with these conditions respond to conventional topical and/or systemic immunosuppressive agents, treatment-resistant cases remain challenging. In these, the use of biologics such as tumour necrosis factor alpha (TNF-α) inhibitors or rituximab may be of benefit. This article reviews the use of biologics in ulcerative oral conditions, highlighting potential benefits, adverse effects and principles of use and future developments. TNF-α inhibitors such as infliximab can be effective in inducing resolution in oral aphthous and aphthous-like ulcers and may be an appropriate therapy in those patients in which disease is severe and refractory to, or patients are intolerant of, traditional immunomodulatory regimens. There would also seem support and rationale for use of biologics (mainly rituximab) in pemphigus but not in oral LP or other oral ulcerative conditions.

show abstract

Section: Vesiculobullous Diseasesmentioning

confidence: 99%

Biologics in oral medicine: ulcerative disorders

O’Neill¹,

Scully²

2012

Oral Diseases

View full text Add to dashboard Cite

show abstract

“…in 2004 and Wallet‐Faber et al . in 2007 reported adults who had EBA following BP, indicating an intermolecular epitope spreading . To the best of our knowledge, ours is the second report of concurrent BP and EBA, and the first report of an adult case.…”

mentioning

confidence: 54%

An autoimmune bullous dermatosis with clinical, histopathological and immunological features of bullous pemphigoid and epidermolysis bullosa acquisita in an adult

et al. 2016

View full text Add to dashboard Cite

“…Table provides an overview of 16 EBA cases treated with rituximab (Cavailhes et al, ; Crichlow et al, ; Iranzo et al, ; Kim et al, ; Lamberts et al, ; McKinley et al, ; Meissner et al, ; Mercader et al, ; Sadler et al, ; Saha et al, ; Schmidt et al, & Wallet‐Faber et al, ). Prior to initiating rituximab therapy, these patients were treated with various agents as presented in Table .…”

Section: Discussion and Review Of The Literaturementioning

confidence: 99%

The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature

Bevans

Sami

2018

Dermatologic Therapy

View full text Add to dashboard Cite

Epidermolysis bullosa acquisita (EBA) is a rare, subepidermal blistering disease affecting the skin and mucous membranes that often remains refractory to standard immunosuppressive therapy. We present three original cases and a review of the literature of 20 cases of refractory EBA treated with rituximab as monotherapy or in combination with other agents. Complete control (with or without therapy) and remission were seen in 56% of patients treated with rituximab monotherapy and 75% of patients treated with rituximab and immunoadsorption (IA). We conclude EBA refractory to standard immunosuppressive therapy may show a more favorable long‐term response to the addition of rituximab; and rituximab in combination with intravenous immunoglobulin or IA may provide utility in terminating acute disease. Additional data are needed to evaluate the safety and long‐term outcomes of rituximab‐based treatment.

show abstract

Epidermolysis Bullosa Acquisita following Bullous Pemphigoid, Successfully Treated with the Anti-CD20 Monoclonal Antibody Rituximab

Cited by 30 publications

References 36 publications

Biologics in oral medicine: ulcerative disorders

Biologics in oral medicine: ulcerative disorders

An autoimmune bullous dermatosis with clinical, histopathological and immunological features of bullous pemphigoid and epidermolysis bullosa acquisita in an adult

The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature

Contact Info

Product

Resources

About